ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS ESCI Q3Scopus Q2SCImago #8,857Hybrid

Drugs in Context

Identifier (ISSN):1745-1981(Print)/1740-4398(Online)
•
Publisher:BioExcel Publishing Ltd
Clarivate JCR Index Advisory: Active (ESCI)
Clarivate IF (2026)
2.2↓ -0.6
Journal Impact Factor
IF Trend↓
WoS Quartile
Q3
WoS ESCIJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2023–2026)

Clarivate IF trend for Drugs in Context

WoS Q3
0134020232.820252.22026
Annual Impact Factor Metric
Current (2026):2.2
Scopus SJR & RankScopus Q2
0.659
#8,857

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
44

44 papers with at least that number of citations each

WoS: ESCIQ3
Self-Citation RateN/A
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
0articles/year
97.48% Gold OA•0% Original Research

Aims & Scope

Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.

Topics Covered (Recognized by AI)
MedicineBiology93.7%Internal medicine86%Pathology62.7%Genetics48.4%Intensive care medicine38%Psychology37.3%Pharmacology36.6%Immunology36.1%Chemistry35.6%Surgery34.9%Biochemistry33.4%Endocrinology32%Psychiatry31.5%Disease28.6%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRESCI2026

PHARMACOLOGY & PHARMACY

Q3
Rank231/356
IndexESCI
JCIESCI2026

PHARMACOLOGY & PHARMACY

Q4
Rank275/356
IndexESCI

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF2.2
Articles / Year33
Total Citations29
2025
IF2.8
Articles / Year50
Total Citations62
2024
IF—
Articles / Year51
Total Citations216
2023
IF0
Articles / Year66
Total Citations609
2022
IF—
Articles / Year66
Total Citations824

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #8,857Scopus Q2SCImago Profile
Scopus Coverage:2006-2008, 2012-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q2
0.659

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
2.32

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,227 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations475
3-Year Documents173
Citable Documents172

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate40.1%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Medicine (miscellaneous)Q2
PharmacologyQ2
Molecular MedicineQ3
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: N/A

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区PHARMACOLOGY & PHARMACY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Drugs in Context (ISSN: 1745-1981) is a peer-reviewed international scholarly journal in the field of Medicine, published by BioExcel Publishing Ltd in United Kingdom. The periodical holds a Journal Impact Factor (JIF) of 2.20, ranking in quartile Q3 of Web of Science (ESCI), a Scopus SJR indicator of 0.659 (Q2), an H-index of 44.

The journal enforces rigorous peer evaluation with an annual output of approximately 0 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,227 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
BioExcel Publishing Ltd
Publication Language
English
Frequency
Periodic
Indexing & Databases
ScopusDOAJPubMed

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: f49d9196-b8d0-4dce-8685-3cfbda6fd254
Database Updated: 2026-10-01